Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology firm focused on briquilimab, announced the appointment of Matthew Ford as Vice President of Human Resources. Ford, who has extensive experience in the pharma industry, previously held a senior HR role at Tricida and has worked with Jazz Pharmaceuticals and Gilead Sciences. His appointment aims to strengthen the company’s leadership and support the ongoing development of briquilimab, which targets diseases like chronic spontaneous urticaria and myelodysplastic syndromes. Jasper's briquilimab is in clinical trials, demonstrating safety and efficacy in over 130 subjects related to various conditions, including sickle cell disease and severe combined immunodeficiency.
Jasper Therapeutics (Nasdaq: JSPR) announced the appointment of David Hinds as Senior Vice President of Development Operations on April 10, 2023. Hinds, who has over 25 years of experience in clinical program development, is expected to play a crucial role in advancing briquilimab, an antibody therapy targeting c-Kit (CD117). This therapy aims to treat chronic spontaneous urticaria and lower-risk myelodysplastic syndromes (MDS) while enhancing stem cell transplant conditioning. CEO Ronald Martell expressed confidence in Hinds' ability to lead the clinical development phase effectively, including studies for chronic spontaneous urticaria and MDS. Jasper has demonstrated briquilimab's safety and efficacy in over 130 subjects and aims to further its development in various therapeutic areas.